Sumatriptan-d6 (succinate) |
| Catalog No.GC48117 |
An internal standard for the quantification of sumatriptan
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1397195-80-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Sumatriptan-d6 is intended for use as an internal standard for the quantification of sumatriptan by GC- or LC-MS. Sumatriptan is an agonist of the serotonin (5-HT) receptor subtypes 5-HT1B and 5-HT1D (IC50s = 9.3 and 7.3 nM, respectively).1 It also binds to the 5-HT1F receptor (IC50 = 17.8 nM). It induces vasoconstriction in isolated human middle meningeal arteries (EC50 = 89.9 nM), an effect that can be reduced by the 5-HT1B/1D receptor antagonists GR125743 and GR127935 . Sumatriptan reduces acute, but not chronic, mechanical hyperalgesia in a mouse model of pain induced by nitroglycerin, which is a known migraine trigger in humans.2 Formulations containing sumatriptan have been used in the treatment of migraine headache.
1.Razzaque, Z., Heald, M.A., Pickard, J.D., et al.Vasoconstriction in human isolated middle meningeal arteries: Determining the contribution of 5-HT1B- and 5-HT1F-receptor activationBr. J. Pharmacol.47(1)75-82(1999) 2.Pradhan, A., Smith, M.L., McGuire, B., et al.Characterization of a novel model of chronic migrainePain155(2)269-274(2014)
Average Rating: 5 (Based on Reviews and 16 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *